Hypertension

 
Racial Disparities in Cardiovascular Disease Outcomes: Daily Dose
June 27, 2024

Your daily dose of the clinical news you may have missed.

George L Bakris, MD, Expert in Hypertension and Metabolic Disease, Has Died
June 20, 2024

Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.

Chronic Hypertension in Pregnancy Increased Two-Fold Between 2008 and 2021
June 20, 2024

The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.

New Report Shows that Despite Gains, Black Americans Still Face Higher Cardiovascular Mortality
June 19, 2024

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Children with HTN Have 2-times Higher Risk of Major Adverse Cardiac Events, According to New Research
May 07, 2024

Findings suggest that optimizing care for children with hypertension may reduce the risk of adult CVD, report researchers.

CV Risk Prevention Profiles Significantly Worse Following Stroke vs MI in 2 Large National Cohorts
May 06, 2024

Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.

Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women
April 19, 2024

Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.

FDA Approves Aprocitentan for Treatment-Resistant HTN: Daily Dose
March 29, 2024

Your daily dose of the clinical news you may have missed.

Michael A. Weber, MD, on aprocitentan approval: A new approach to managing hypertension
March 21, 2024

Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision
March 20, 2024

Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.